September 11, 2017

MediWound’s NexoBrid® Wins Best Poster Presentation Award at the 17th European Burns Association Congress

Award-winning Poster Underscores European Consensus on Benefits of NexoBrid

YAVNE, Israel, Sept. 11, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that a scientific poster highlighting European consensus statements on the benefits of NexoBrid was awarded "Best Poster Presentation" at the European Burns Association (EBA) Congress. The poster, titled “Escar removal by Bromelain based Enzymatic Debridement (NexoBrid®) in Burns: European Consensus Guidelines,” was delivered by Dr. C. Hirche, University of Heidelberg, BG Trauma Center, Ludwigshafen, Germany, at the EBA Congress in Barcelona, Spain on September 6-9, 2017.

The poster listed 68 different consensus statements regarding the use and benefits of NexoBrid, which were agreed upon by leading burn specialists from prominent burn centers across Europe after accumulating mutual experience in the treatment of over 500 patients with NexoBrid. The consensus statements will be published in a subsequent comprehensive scientific publication that can serve as preliminary European guidelines on the use of NexoBrid until final guidelines are adopted. The poster emphasizes that early eschar removal with NexoBrid is a significant step in treating severe burns and can improve outcomes by reducing infections rate, number of wounds requiring surgical excision, blood loss, need for autografting and hospital length of stay.

"We are very excited that for the third consecutive year, a scientific presentation highlighting the therapeutic merits of NexoBrid was awarded best presentation in a premier burn conference. The consensus of this leading group of key opinion leaders from throughout Europe and the endorsement of the consensus statements by the European Burn Association award, underscore the growing conviction among experts of the benefits of NexoBrid and its place in the standard-of-care of burns," noted Gal Cohen, President and Chief Executive Officer of MediWound. "We would like to thank each of the authors of the 43 presentations on NexoBrid at the international EBA congress for documenting and sharing their NexoBrid experience with the hundreds of burn care specialists who attended this important event. We also thank them for advancing evidence-based medicine for the benefit of burn patients."

The winning poster can be accessed here.

About the European Burns Association Congress
The European Burns Association serves as a resource for burn care specialists by facilitating the communication and collaboration between them. The EBA hosts the Congress every other year with the aim to provide a forum for the exchange and exploration of new ideas, current outcomes and future perspectives. This year’s Congress focused on burn care from every perspective: from the patient’s journey to the interaction of all team members, with an emphasis on current evidence-based delivery of care, quality of care, and outcome measurement.

About NexoBrid
NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues. NexoBrid received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, and is commercially available in Europe, Israel, and Argentina. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or “debridement” is a critical first step in the successful healing of severe burns as well as chronic and other hard-to-heal wounds. With the current standard of care, burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue necessitating further surgical treatments. The U.S. Phase 3 clinical trial, pediatric phase 3 study and registration process for NexoBrid in the U.S. is being funded in whole or in part with federal funds under a contract with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.

About MediWound Ltd.
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe
burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. MediWound's first innovative biopharmaceutical product, NexoBrid®, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns and was launched in Europe, Israel, and Argentina. NexoBrid® represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier, relative to the existing standard of care, without harming viable tissues.

MediWound's second innovative product candidate, EscharEx®, is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from existing development data on NexoBrid®. In January 2017, MediWound reported final results from the first cohort of its second phase 2 study evaluating EscharEx for the debridement of chronic and other hard-to-heal wounds in which EscharEx met its primary endpoint demonstrating higher incidence of complete debridement with statistical significance. For more information, please visit www.mediwound.com.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2016 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Contacts:
Sharon Malka
Chief Financial & Operation Officer
MediWound Ltd.
ir@mediwound.co.il

Bob Yedid
Managing Director
LifeSci Advisors
bob@lifesciadvisors.com

Source: MediWound Ltd.